Recent Updates
Recently added Catalysts
BMRN Positive Sentiment Score: 60/100

BioMarin to Participate in Three Upcoming Investor Conferences BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that company management will present at three upcoming investor conferences in September....

Key Takeaway: BioMarin Pharmaceutical Inc. has announced its participation in three upcoming investor conferences in September 2023. Company management will provide insights during these presentations, which will be accessible through live audio webcasts. Following the events, archived versions of the presentations will also be available on the company's website. This engagement reflects BioMarin's ongoing commitment to informing stakeholders about its advancements in biotechnology.

Market Sentiment Analysis

POSITIVE FACTORS

  • BioMarin will present at three investor conferences, enhancing visibility.
  • The company showcases its commitment to transparency through live webcasts.

Full Press Release Details

SAN RAFAEL, Calif. , Sept. 5, 2023 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) today announced that company management will present at three upcoming investor conferences in September.
An audio webcast of the presentations will be available live. You can access the webcasts at: https://investors.biomarin.com/ . An archived version of the remarks will also be available through the Company's website for a limited time following the conference.
About BioMarin Founded in 1997, BioMarin is a global biotechnology Company dedicated to transforming lives through genetic discovery. The Company develops and commercializes targeted therapies that address the root cause of the genetic conditions. BioMarin's unparalleled research and development capabilities have resulted in eight transformational commercial therapies for patients with rare genetic disorders. The Company's distinctive approach to drug discovery has produced a diverse pipeline of commercial, clinical, and pre-clinical candidates that address a significant unmet medical need, have well-understood biology, and provide an opportunity to be first-to-market or offer a substantial benefit over existing treatment options. For additional information, please visit www.biomarin.com .
Contacts:
Investors Media
Traci McCarty Marni Kottle
BioMarin Pharmaceutical Inc. BioMarin Pharmaceutical Inc.
(415) 455-7558 (650) 374-2803
SOURCE BioMarin Pharmaceutical Inc.

21 %

Frequently Asked Questions

When will BioMarin present at investor conferences?

BioMarin will present at three investor conferences in September 2023.

How can I access BioMarin's conference presentations?

Access live webcasts of the presentations at https://investors.biomarin.com/.

What is BioMarin known for?

BioMarin is known for developing therapies for rare genetic disorders.

When was BioMarin founded?

BioMarin was founded in 1997 and focuses on genetic discovery.

What type of therapies does BioMarin develop?

BioMarin develops targeted therapies addressing the root causes of genetic conditions.

Last updated: Sep 5, 2023